# Fermenta Biotech share price today (Fermenta Biotech Ltd, NSE: FERMENTA)

> Fermenta Biotech share price today: ₹439.80 at the NSE close on 4 November 2026, up 57.9% in a year. Fermenta Biotech (NSE: FERMENTA) is worth ₹1,293 crore, trades at a P/E of 23.6 and has closed between ₹269.00 and ₹559.55 over the past 52 weeks. > Fermenta Biotech Ltd's share price has risen faster than its earnings: +57.9% in a year, against −6.6% for earnings per share. FERMENTA · Pharma - API · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/fermenta-biotech-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹439.80 (+57.9% in a year)
- P/E: 23.6× (higher than 73% of the last 11 years)
- Revenue (Jun 2026): ₹122 Cr (−10.6% on a year ago)
- Profit (Jun 2026): ₹9.5 Cr (−55.9% on a year ago)
- Operating margin: 14.8% (−5.9 points on a year ago)
- ROCE: 21%, FY26
- ROIC: 10.1%, against a 12.0% cost of capital: −1.9 points
- Profit that came in as cash: 110%, last 3 years

The main question: the share price moved +57.9% in a year while yearly earnings per share moved −6.6%. The difference came from the market paying a higher multiple. ## What is the Fermenta Biotech share price today? Fermenta Biotech Ltd's share price was ₹439.80 at the close on 4 November 2026. It has been rising for 17 weeks. That is 7.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹269 and ₹560, and at that close it sat 59% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row. Over the last 11 years the share price moved +628% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Fermenta Biotech this quarter? Three changes stood out: promoters cut their stake by 4 points in one quarter, lowest operating margin in 8 quarters and foreign funds (FIIs) raised their stake for 3 quarters in a row. 1. Promoters cut their stake by 4 points in one quarter From 64.1% to 60.1% in the September 2026 quarter. 2. Lowest operating margin in 8 quarters Operating margin was 14.8% in the June 2026 quarter, against 20.7% a year earlier. 3. Foreign funds (FIIs) raised their stake for 3 quarters in a row From 0% to 1.1% of the company by the September 2026 quarter. ## What are Fermenta Biotech's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Fermenta Biotech reported revenue of ₹122 crore, down 10.6% from ₹136 crore a year earlier, and a profit of ₹9.53 crore, down 55.9% from ₹21.6 crore. ### Fermenta Biotech results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹122 crore | ₹136 crore | −10.6% |
| Profit | ₹9.53 crore | ₹21.6 crore | −55.9% |
| Earnings per share | ₹3.31 | ₹7.42 | −55.4% |
| Operating margin | 14.8% | 20.7% | −5.9 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Fermenta Biotech share price history? Fermenta Biotech closed at ₹439.80 on 4 November 2026, up 57.9% from ₹278.60 a year earlier (7 November 2025) and up 44.1% over five years. Its highest weekly close since March 2016 was ₹559.55 on 7 August 2026. ### Fermenta Biotech share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹417.55 | +5.3% |
| 1 month ago · 1 Oct 2026 | ₹551.35 | −20.2% |
| 6 months ago · 8 May 2026 | ₹288.70 | +52.3% |
| 1 year ago · 7 Nov 2025 | ₹278.60 | +57.9% |
| 3 years ago · 3 Nov 2023 | ₹176.35 | +149.4% |
| 5 years ago · 4 Nov 2021 | ₹305.10 | +44.1% |
| 10 years ago · 4 Nov 2016 | ₹68.25 | +544.4% |
| Earliest weekly close in our records · 10 Mar 2016 | ₹60.42 | +627.9% |
| Highest weekly close since March 2016, also the 52-week high · 7 Aug 2026 | ₹559.55 | −21.4% |
| Lowest weekly close since March 2016 · 22 Sep 2017 | ₹53.55 | +721.3% |
| 52-week low (weekly close) · 5 Dec 2025 | ₹269.00 | +63.5% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (558 weekly closes from 10 March 2016 to 4 November 2026.)

## What is the latest news on Fermenta Biotech? 4 Nov 2026: Fermenta Biotech closed at ₹439.80, up 5.3% on the week and down 20.2% on the month. 5 Aug 2026: ex-date for a dividend of ₹3.75 a share. ### Earlier

- Results for April to June 2026: Revenue down 10.6% and profit down 55.9% on a year earlier. ## What dividend does Fermenta Biotech pay? Fermenta Biotech paid ₹3.75 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.85% at the ₹439.80 close on 4 November 2026. The last was a dividend of ₹3.75 a share, ex-date 5 August 2026. ### Fermenta Biotech dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 5 Aug 2026 | ₹3.75 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Fermenta Biotech Ltd paid out 15% of its profit as dividends in FY26, and it paid a dividend in 9 of its last 13 reported years. 4 of those years show a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Fermenta Biotech management say on the latest results call? Fermenta Biotech's management made 0 promises we could check against what it later reported. (Our read after the latest results, written 17 May 2026.)

## What is the future of Fermenta Biotech? What is changing in the business? What is changing at Fermenta Biotech, from the latest results and calls: vitamin d3 demand recovery, channel inventory normalisation, plant-based vitamin d3 patent + ₹110 crore capital spending and geographic expansion, 60+ country footprint deepening. - Vitamin D3 Demand Recovery, Channel Inventory Normalisation. 9M FY26 ex-real-estate operating profit already +14% above full FY25. ⚠ estimate
- Geographic Expansion, 60+ Country Footprint Deepening. Revenue mix well-diversified: India 40%, Europe 27%, North America 17%, Others 16% (FY25). Limited concentration, top customer only 9% of revenue. 400+ customers across 60+ countries. ⚠ estimate
- Green Chemistry / Enzyme Revenue Diversification. Green Chemistry Solutions revenue +64% on a year earlier in 9M FY26; FY25 green chemistry at ₹38 crore vs ₹29 crore in FY24. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the latest results, written 17 May 2026.)

## What could change the Fermenta Biotech story? What are the risks? October to December 2025 operating margin compressed to 18%, normalised band may be 18-22%, not 25-34%. ### The main risks

- Operating margin Cyclicality, FY25 Peak May Not Recur: October to December 2025 operating margin compressed to 18%, normalised band may be 18-22%, not 25-34%. ⚠ estimate
- Real Estate Revenue Non-Recurrence: Real estate segment revenue declined 95% on a year earlier in 9M FY26; FY25 included ₹45 crore real estate. This non-recurring element inflated FY25 profitability and is now absent from FY26. ⚠ estimate
- Institutional Ownership Desert, Low Market Profile: FII at 0.02%, DII at 0%, essentially zero institutional ownership. Stock was BSE-only until NSE permitted to trade admission in Apr 2026. Market discovery dependent on retail interest. ⚠ estimate

(Our read after the latest results, written 17 May 2026.)

## What to watch in Fermenta Biotech's next results? When Fermenta Biotech reports July to September 2026, these are the 5 checks that show whether the story is still on course. First: CARE Ratings annual review / Fermenta realisation per kg D3 in quarterly disclosures. | What to check | Why |
| --- | --- |
| CARE Ratings annual review / Fermenta realisation per kg D3 in quarterly disclosures. | Chinese Vitamin D3 Competition, Animal Feed Segment Pricing |
| January to March 2026 and April to June 2026 operating margin trends; real estate revenue contribution declining to zero. | Operating margin Cyclicality, FY25 Peak May Not Recur |
| First commercial sale of VITADEE Green; customer qualification announcements. | Plant-Based D3 Capital spending Execution Risk |
| Any further real estate transaction disclosures; FY26 consolidated vs standalone results divergence. | Real Estate Revenue Non-Recurrence |
| NSE listing volume growth. | Institutional Ownership Desert, Low Market Profile |

## Which stock lists is Fermenta Biotech on? Fermenta Biotech is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 1294.489761705185](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Fermenta Biotech profitable? Fermenta Biotech Ltd earned ₹9.5 Cr of net profit in the Jun 2026 quarter, −55.9% on the same quarter a year earlier. Full-year FY26 profit was ₹70.0 Cr. Over 10 years profit has grown 42.7% a year on average. That is 7.8% of the quarter's revenue. The same quarter a year earlier earned ₹21.6 Cr. 3 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹70.0 Cr (−7.9% on the year before). Why profit moved: revenue changed −10.6% on a year earlier and the margin moved −5.9 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −26.6% and revenue +0.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Fermenta Biotech make, and is it growing? Fermenta Biotech Ltd reported ₹122 Cr of revenue in the Jun 2026 quarter, −10.6% on the same quarter a year earlier. Over 10 years it has grown 12.9% a year on average. The last full year, FY26, came in at ₹523 Cr. The last four reported quarters add to ₹511 Cr. Why this happened. The company received an Indian Patent for its plant-based Vitamin D3 manufacturing process in September 2025. MD Prashant Nagre stated: 'Plant-based Vitamin D3 represents the future of nutrition, and this patent reinforces our ability to deliver differentiated offerings that create long-lasting impact.' The company has completed validation batches of VITADEE Green (plant-source D3 in oil and spray-dried variants) and is in the qualification process with leading global customers. The global shift away from lanolin-derived cholecalciferol toward vegan alternatives is a structural trend cited by multiple industry reports (Technavio: CAGR 7.1% 2025-2030, with plant-based as a key driver).…

FY26 revenue was ₹523 Cr, +11.8% on the year before. Recent pace: the last four quarters grew +0.3% on average, against 12.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −3.2%, against +24.2% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does Fermenta Biotech keep? Fermenta Biotech Ltd's operating margin was 14.8% in the Jun 2026 quarter, 5.9 percentage points lower than the same quarter a year ago. Across 13 years it has been between 5.0% and 39.0%. The latest quarter is within that range. Why this happened. Fermenta's FY23 and FY24 losses were directly caused by two factors: (1) channel inventory built during COVID demand spikes took 2 years to normalise, suppressing human nutrition D3 off-take; (2) Chinese capacity expansion compressed animal feed D3 realisations. Both headwinds abated in FY25. The recovery was sharp. CARE Ratings confirmed: 'demand has recovered in FY25 with normalisation of channel inventory in Vitamin D3 products for human consumption, relative stability in realisations in Vitamin D3 products for animal consumption and increased realisation of Vitamin D3 products for human consumption.' 9M FY26 saw Human Nutrition D3 volume +46% YoY and Animal Nutrition +52%. However, Q3…

Why the margin moved: operating margin changed −5.9 percentage points on the year while gross margin changed +3.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Fermenta Biotech's profit turning into cash? Over the last 3 years, 110% of Fermenta Biotech Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹93.0 Cr of operating cash against ₹70.0 Cr of profit. After ₹12.0 Cr of spending on assets, ₹81.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 110% of profit came in as cash: the cash cycle got 117 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: it has been selling more assets than it buys. The next section shows those figures. ## Where does Fermenta Biotech's cash go? Fermenta Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 221 days in FY26, down from 338 days in FY21. Over the last 3 years it sold more assets than it bought, by ₹8.0 Cr. Customers take 78 days to pay, and stock sits for 290 days on average. At FY26 sales of ₹523 Cr, each day of that cycle ties up about ₹1.4 Cr, so roughly ₹317 Cr is tied up in the business at any time. FY26: customers took 78 days to pay and stock sat for 290 days, about 9.5 months of sales sitting as stock, for a full cycle of 221 days, shorter than FY21's 338. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 290 days. Customers pay about 78 days after that. Suppliers are paid at 147 days. Together that makes the 221-day cycle. Over the last 3 years, money from selling assets was ₹8.0 Cr more than it spent on new ones. Work still in progress is ₹13.0 Cr (FY26). In short: assets are being sold, not built, so this cash is not going into new capacity. ## What is Fermenta Biotech's P/E ratio, and how does it compare with its own history? Fermenta Biotech Ltd's P/E is 23.6×, near the high end of its own history: higher than 73% of past readings. Its usual P/E (the middle reading) is 17.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹20.28. Why the multiple is where it is: over the past year earnings per share moved −6.6% while the price moved +57.9%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +7.6% a year; about +4.8% a year came from earnings growth and about +2.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Fermenta Biotech share price assume? Worked out from its price on 20 July 2026, Fermenta Biotech Ltd's share price assumed profit growth of about 8.9% a year. Over the past 10 years its profit actually grew 42.7% a year. Today its P/E is 23.6×, higher than 73% of its own last 11 years. This is a one-day reading, taken on 20 July 2026. Every other number on this page, the multiple included, uses the latest price as of 4 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Fermenta Biotech business getting better or worse? Fermenta Biotech Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## What is the Fermenta Biotech story, and has it been checked? Fermenta Biotech Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: EARLY EXPANSION. Our read, 17 May 2026. A structural Vitamin D3 turnaround, margin peak may have passed, but plant-based D3 patent creates a multi-year premium moat if commercialisation lands. From the numbers. EPS…

From the price. Price stage 2, week 17, above its 200-day line, relative strength falling. From the research. A structural Vitamin D3 turnaround, margin peak may have passed, but plant-based D3 patent creates a multi-year premium moat if commercialisation lands. Where they disagree. EPS has been volatile: negative FY23-FY24, strong FY25, now decelerating in FY26. pe pb cycle segment EXPANSION STARTED, RIDING WAVE. The pe decomposition flag is MIXED (EARNINGS DISCONNECT), EPS improvement is real but PAT in FY26 is decelerating from FY25 peak. What is proven. A structural Vitamin D3 turnaround, margin peak may have passed, but plant-based D3 patent creates a multi-year premium moat if commercialisation lands. What is not proven yet. Chinese manufacturers dominate animal feed D3 with price-competitive capacity; CARE Ratings flagged margins susceptible to volatility of commodity prices and competition from China under feed grade segment. The test written in advance. Chinese Vitamin D3 Competition, Animal Feed Segment Pricing. Measured by: Chinese Vitamin D3 Competition, Animal Feed Segment Pricing CARE Ratings annual review / Fermenta realisation per kg D3 in quarterly disclosures by the next result. The test written in advance. OPM Cyclicality, FY25 Peak May Not Recur. Measured by: OPM Cyclicality, FY25 Peak May Not Recur Q4 FY26 and Q1 FY27 OPM trends; real estate revenue contribution declining to zero by the next result. The test written in advance. Plant-Based D3 Capex Execution Risk. Measured by: Plant-Based D3 Capex Execution Risk First commercial sale of VITADEE Green; customer qualification announcements by the next result. Lever 1 · Operating leverage: building. Post-pandemic channel inventory overhang cleared; human nutrition D3 realisations recovered, drove FY25 PAT from loss to Rs 76 Cr. 9M FY26 ex-real-estate EBITDA already +14% above full FY25. What proves it keeps working: Vitamin D3 Demand Recovery, Channel Inventory Normalisation. It stops working if CARE Ratings annual review / Fermenta realisation per kg D3 in quarterly disclosures. Lever 7 · Consolidation: building. Indian patent granted Sep 2025 for proprietary plant-based D3 process; Rs 110 Cr capex for commercial scale production, goals premium vegan supplement markets globally where premiums over lanolin D3 are structurally higher. What proves it keeps working: Plant-Based Vitamin D3 Patent + Rs 110 Cr Capex. It stops working if CARE Ratings annual review / Fermenta realisation per kg D3 in quarterly disclosures. Lever 10 · New geographies: building. Revenue mix well-diversified: India 40%, Europe 27%, North America 17%, Others 16% (FY25). Limited concentration, top customer only 9% of revenue. 400+ customers across 60+ countries. What proves it keeps working: Geographic Expansion, 60+ Country Footprint Deepening. It stops working if CARE Ratings annual review / Fermenta realisation per kg D3 in quarterly disclosures. Lever 12 · New product launch: building. Green Chemistry Solutions revenue +64% YoY in 9M FY26; FY25 green chemistry at Rs 38 Cr vs Rs 29 Cr in FY24. Diversification reduces single-product D3 revenue concentration. What proves it keeps working: Green Chemistry / Enzyme Revenue Diversification. It stops working if CARE Ratings annual review / Fermenta realisation per kg D3 in quarterly disclosures. Sources: our stock research file (17 May 2026) · quarterly results through Jun 2026. The story check is re-scored every results season; the record below never changes. ## How much does Fermenta Biotech earn on its capital? Fermenta Biotech Ltd earned a ROCE of 21% in FY26. That is up from a low of 0% in FY23. Its return on capital used (ROIC) is 1.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 13.4% net margin and 0.81× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 13.4% net margin × 0.81× asset turnover × 1.60× leverage (assets divided by equity) ≈ 17.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 10.1% − 12.0% = −1.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 10.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 13.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Fermenta Biotech have too much debt? Fermenta Biotech Ltd has total debt of ₹113 Cr against shareholder equity of ₹401 Cr as of Jun 2026, so its debt is 0.28× its equity, which is very little. Year by year, that ratio went from 0.64 in FY22 to 0.28 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Fermenta Biotech shareholding pattern? Promoters cut their stake in Fermenta Biotech Ltd by 1.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 60.1% of the company. Foreign institutions moved +1.0 points over the same period, to 1.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −1.9 points over 8 quarters, to 60.1%; Foreign institutions: +1.0 points over 8 quarters, to 1.1%; Domestic institutions: +0.0 points over 8 quarters, to 0.0%. Why the owners changed: promoters drove it (−1.9 points), with the other side taken by foreign institutions (+1.0 points). They reduced their stake. ## How far is Fermenta Biotech from balance-sheet trouble? For Fermenta Biotech Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Fermenta Biotech rank in its industry? 42.8 out of 100, rank 11 of 14 in Pharma - API, with 64% of the evidence available. Fermenta Biotech Ltd scores 42.8 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 11. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 3.8 + 16.7 + 10.8 + 11.5 = 42.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Fermenta Biotech compared with? Fermenta Biotech ranks 11 of 14 Pharma - API companies on the 4-Factor Sector Score, with 42.8 out of 100. 1. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ANUHPHR · breaking out · Evidence leans up · 100% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 6.6% · Profit 23.7% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 14.9% · Operating margin 9% · 100% evidence Valuation 17.8/20 · P/E 18.3× · PEG 0.31 · 100% evidence Relative strength 11.5/20 · Lead over its industry -7.9% · Lead over NIFTY 500 14.5% · 1 year -3.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 13.8 + 17.8 + 11.5 = 64.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) SENORES · quiet · Evidence leans up · 75% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 38.9% · Profit 62.4% · Operating margin change -1 points · 95% evidence Capital efficiency 16.4/25 · ROCE 15.1% · Operating margin 30% · 76% evidence Valuation 9.2/20 · P/E 39.1× · PEG n/a · 15% evidence Relative strength 7.4/20 · Lead over its industry -6.3% · Lead over NIFTY 500 12.6% · 1 year 47% · 100% evidence · 7 of 12 weeks ahead Exact sum: 28.2 + 16.4 + 9.2 + 7.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) INNOVACAP · leader · Evidence leans up · 96% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 34.4% · Profit 18.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.0/25 · ROCE 15% · Operating margin 16% · 100% evidence Valuation 7.3/20 · P/E 38.1× · PEG 4.06 · 100% evidence Relative strength 15.8/20 · Lead over its industry 3.4% · Lead over NIFTY 500 25.3% · 1 year 23.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 13 + 7.3 + 15.8 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) BETA · losing its lead · Evidence leans up · 67% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 15.3% · Profit 26.2% · Operating margin change 1 points · 95% evidence Capital efficiency 18.4/25 · ROCE 19.2% · Operating margin 22% · 76% evidence Valuation 8.0/20 · P/E 38.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Lead over its industry n/a · Lead over NIFTY 500 11.2% · 1 year -3.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 19.8 + 18.4 + 8 + 10.5 = 56.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) INDSWFTLAB · leader · Evidence leans up · 82% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 29.9% · Profit -64.1% · Operating margin change 14.3 points · 95% evidence Capital efficiency 8.3/25 · ROCE 4.9% · Operating margin 19% · 76% evidence Valuation 7.1/20 · P/E 34.9× · PEG n/a · 50% evidence Relative strength 20.0/20 · Lead over its industry 71.6% · Lead over NIFTY 500 98.2% · 1 year 257.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 8.3 + 7.1 + 20 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) WANBURY · quiet · Evidence leans up · 81% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 3.6% · Profit 30% · Operating margin change -5.2 points · 88% evidence Capital efficiency 16.6/25 · ROCE 30.7% · Operating margin 9.8% · 100% evidence Valuation 19.2/20 · P/E 11.2× · PEG 0.34 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -27.9% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12 + 16.6 + 19.2 + 7.5 = 55.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) GUJTHEM · turning · Evidence leans up · 89% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 16.1% · Profit 6.7% · Operating margin change 9 points · 88% evidence Capital efficiency 18.1/25 · ROCE 18.1% · Operating margin 48% · 100% evidence Valuation 10.3/20 · P/E 97.1× · PEG 1.33 · 65% evidence Relative strength 7.2/20 · Lead over its industry -16.3% · Lead over NIFTY 500 3.7% · 1 year -21.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.6 + 18.1 + 10.3 + 7.2 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) AARTIDRUGS · turning · Evidence leans up · 96% evidence 50.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.5/35 · Revenue 10.5% · Profit 1.1% · Operating margin change 1 points · 88% evidence Capital efficiency 13.4/25 · ROCE 12% · Operating margin 14% · 100% evidence Valuation 8.2/20 · P/E 20.6× · PEG 3.2 · 100% evidence Relative strength 12.0/20 · Lead over its industry -6.8% · Lead over NIFTY 500 15.8% · 1 year -11.3% · 100% evidence · 9 of 12 weeks ahead Exact sum: 16.5 + 13.4 + 8.2 + 12 = 50.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) JAGSNPHARM · breaking out · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6% · Profit -27% · Operating margin change -1 points · 100% evidence Capital efficiency 19.1/25 · ROCE 22.7% · Operating margin 21% · 100% evidence Valuation 6.4/20 · P/E 30.2× · PEG 3.39 · 100% evidence Relative strength 6.4/20 · Lead over its industry -10.7% · Lead over NIFTY 500 9.9% · 1 year -2.7% · 100% evidence · 7 of 12 weeks ahead Exact sum: 14.6 + 19.1 + 6.4 + 6.4 = 46.5 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 10. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) AARTIPHARM · breaking out · Evidence leans down · 85% evidence 44.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 13.4% · Profit 6.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 10.7% · Operating margin 22% · 100% evidence Valuation 2.9/20 · P/E 30.4× · PEG 5.52 · 100% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 22.9% · 1 year 2.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 12.4 + 2.9 + 11.8 = 44.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. Fermenta Biotech Ltd this page FERMENTA · losing its lead · Evidence leans down · 64% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 3.8/35 · Revenue -3.1% · Profit -44% · Operating margin change -5.9 points · 88% evidence Capital efficiency 16.7/25 · ROCE 20.6% · Operating margin 14.8% · 100% evidence Valuation 10.8/20 · P/E 22.4× · PEG n/a · 15% evidence Relative strength 11.5/20 · Lead over its industry n/a · Lead over NIFTY 500 17.3% · 1 year 51.5% · 25% evidence · 11 of 12 weeks ahead Exact sum: 3.8 + 16.7 + 10.8 + 11.5 = 42.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 12. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) KOPRAN · breaking out · Evidence leans down · 81% evidence 41.5 out of 100 Growth Capital Valuation Relative
13. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ORCHPHARMA · losing its lead · Evidence leans down · 66% evidence 37.8 out of 100 Growth Capital Valuation Relative
14. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) THEMISMED · quiet · Most evidence points down · 71% evidence 30.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API](https://www.sectoralpha.in/sectors/pharma-api), all 14 compared on one page. ## Which companies are close to Fermenta Biotech in size? Fermenta Biotech is the 10th largest of 14 Pharma - API companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Ind-Swift Laboratories, Beta Drugs and Jagsonpal Pharmaceuticals. Just below it: Kopran, Anuh Pharma and Themis Medicare. ### Pharma - API companies close in size

1. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) ₹3,202 crore
2. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) ₹2,000 crore
3. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) ₹1,427 crore
4. Fermenta Biotech Ltd ₹1,229 crore
5. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) ₹1,155 crore
6. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ₹875 crore
7. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) ₹873 crore

[All 14 Pharma - API companies, largest first](https://www.sectoralpha.in/sectors/pharma-api#all-companies)

### Companies close in size in other industries

1. [Capacite Infraprojects Ltd](https://www.sectoralpha.in/stocks/capacite-infraprojects-ltd) ₹1,232 crore · Realty - Construction & Contracting
2. [Eimco Elecon (India) Ltd](https://www.sectoralpha.in/stocks/eimco-elecon-indialtd) ₹1,231 crore · Capital Goods - Engineering Heavy
3. Fermenta Biotech Ltd ₹1,229 crore
4. [Bharat Seats Ltd](https://www.sectoralpha.in/stocks/bharat-seats-ltd) ₹1,228 crore · Auto Ancillaries - Seats
5. [Walchandnagar Industries Ltd](https://www.sectoralpha.in/stocks/walchandnagar-industries-ltd) ₹1,225 crore · Capital Goods - Engineering Heavy

## What else do people ask about Fermenta Biotech? ### What is Fermenta Biotech's share price today? Fermenta Biotech Ltd's share price is ₹439.80, +57.9% over the past year. The whole company is worth ₹1,293 Cr on the market. In the last 52 weeks it traded between ₹269 to ₹560; today it is 59% of the way up from the low, 7.3% above its 200-day average (as of 4 November 2026). ### What were Fermenta Biotech's latest quarterly results? Fermenta Biotech Ltd reported revenue of ₹122 Cr and net profit of ₹9.5 Cr for the Jun 2026 quarter. Revenue fell 10.6% and profit fell 55.9% compared with a year earlier. Earnings per share were ₹3.31. The operating margin was 14.8%, 5.9 percentage points lower than a year earlier (as of 4 November 2026). ### What is Fermenta Biotech's market cap? Fermenta Biotech Ltd's market capitalisation is ₹1,293 Cr at a share price of ₹439.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Fermenta Biotech performing? Fermenta Biotech Ltd's share price has been rising for 17 weeks. In its latest quarter, revenue fell 10.6% and profit fell 55.9% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 1 week running (as of 4 November 2026). ### Will Fermenta Biotech's share price go up? This page does not forecast Fermenta Biotech Ltd's share price. What it shows instead: the share price is ₹439.80, and it has been rising for 17 weeks. Its P/E of 23.6× is higher than 73% of its own last 11 years (as of 4 November 2026). ### Who owns Fermenta Biotech? Promoters own 60.1% of Fermenta Biotech Ltd, foreign institutions 1.1%, domestic institutions 0.0% and the public 36.4% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 1.9 percentage points over 8 quarters (as of 4 November 2026). ### Does Fermenta Biotech have too much debt? No, Fermenta Biotech Ltd has little debt: its debt is 0.28× its equity, and its operating profit is 8 times its interest bill. FY26 borrowings were ₹113 Cr against equity of ₹406 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### What is Fermenta Biotech's capex? Fermenta Biotech Ltd sold more long-term assets (plants, machines and the like) than it bought over the last 3 years, by ₹8.0 Cr, worked out from the change in fixed assets plus depreciation. Depreciation over the same years was ₹71.0 Cr (as of 4 November 2026). ### Where is Fermenta Biotech in its business cycle? Fermenta Biotech Ltd's FY26 operating margin was 19.0%, against a 13-year range of 5.0% to 39.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 14.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Fermenta Biotech story? The main question: the share price moved +57.9% in a year while yearly earnings per share moved −6.6%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Fermenta Biotech a stock worth studying right now? What the numbers show: Fermenta Biotech Ltd's share price has risen faster than its earnings: +57.9% in a year, against −6.6% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Fermenta Biotech share price forecast for 2026? What is changing at Fermenta Biotech, from the latest results and calls: vitamin d3 demand recovery, channel inventory normalisation, plant-based vitamin d3 patent + ₹110 crore capital spending and geographic expansion, 60+ country footprint deepening. What would change the story: October to December 2025 operating margin compressed to 18%, normalised band may be 18-22%, not 25-34%. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.